2216 (2216) Fair Value & Analysis

Healthcare · Market cap HK$369M

2 2216 2216 · HK

PriceHK$0.7000

Fair ValueHK$0.2400

Upside-65.7%

Quality34/100

Watch 2216 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$0.1600 – HK$0.3000

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −22.2% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.5600 – HK$3.59 · fair‑value band HK$0.1600 – HK$0.3000 · the HK$0.7000 price screens above the HK$0.2400 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2216 (2216) currently trades at HK$0.7000, while our model-based Fair Value estimate is HK$0.2400 — implying the stock looks roughly 65.7% overvalued today. We read business quality at 34/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at HK$174K. Revenue declined 55.4% year over year. It earns a return on equity of -11.2%. The balance sheet holds a net cash position of HK$31.9M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$174K

Revenue growth (YoY) -55.4%

Return on equity -11.2%

Free cash flow −HK$10.0M FY2025

Operating margin 818%

EPS (TTM) HK$-0.0200

More key figures

Net cash HK$31.9M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2216 reported revenue of HK$174K in FY2025 versus HK$10.9M in FY2021, a compound −64.4%/yr. Reported net income was −HK$17.9M in FY2025.

Revenue −64.4%/yr

FY21 HK$10.9M

FY22 HK$9.4M

FY23 HK$10.3M

FY24 HK$8.1M

FY25 HK$174K

Net income

FY21 −HK$236M

FY22 −HK$28.0M

FY23 −HK$28.1M

FY24 −HK$15.3M

FY25 −HK$17.9M

Is 2216 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	1,231 MXN	-23%
Abbott Laboratories, ABTT34	R$39.41	R$30.42	-23%
Stryker Corporation S1YK34	R$79.21	R$43.74	-45%
Medtronic plc MDT	$81.67	$60.02	-27%
Boston Scientific Corporation B1SX34	R$229.30	R$43.33	-81%
Edwards Lifesciences Corporation EW	$85.98	$41.02	-52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2216 (2216) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.2400 versus a price of HK$0.7000 — about −66% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2216?

Our model-based fair value for 2216 is HK$0.2400 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.7000.

What is the quality score of 2216?

2216 has a Quality Score of 34/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2216 (2216)?

2216 reported trailing-twelve-month revenue of about HK$174K (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2216?

The net profit margin of 2216 is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.